glp-1 receptor agonist over the counter Medications for Weight Loss *Based on a 2024 survey of pharmacists who recommend branded vitamins and supplements Evolution of GLP‐1 Receptor Agonists

Buteau, J

References 1.Mller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschp MH

As in previous studies, we classified patents into those filed before FDA approval (pre-approval patents) and after (post-approval patents), and we classified regulatory exclusivities into those granted at FDA approval (approval exclusivities) and after (post-approval exclusivities)

Gimeno for their support of the project and helpful discussions on the manuscript

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

Tirzepatide has been available since 2022, with extensive global clinical experience and FDA approval